Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31021926 | 1.00 | ALOX5 (1.00) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL9645814 | 0.90 | ALOX5 (1.00) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL8662838 | 0.79 | ALOX5 (0.66) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL6579918 | 0.79 | ALOX5 (0.66) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL29848289 | 0.79 | ALOX5 (0.66) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL10866792 | 0.79 | ALOX5 (0.65) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL9299293 | 0.79 | ALOX5 (1.00) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| SCHEMBL30015009 | 0.74 | CRBN (0.66) | ALOX5MAPTADRB1 | |
| SCHEMBL29386746 | 0.73 | ALOX5 (0.58) | ALOX5G6PDALOX15ALOX12PTGS1 | |
| Phenidone SCHEMBL10904906 | 0.73 | ALOX5 (1.00) | ALOX5G6PDALOX15ALOX12PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874144-B | Process for preparing 4-bromo-N-arylpyrazole compound | 曲靖师范学院 | 2024-07-05 | — | — | CN | claimed |
| CN-114874144-A | Process for preparing 4-bromo-N-arylpyrazole compound | 曲靖师范学院 | 2022-08-09 | — | — | CN | claimed |
| CN-114874144-B | Process for preparing 4-bromo-N-arylpyrazole compound | 曲靖师范学院 | 2024-07-05 | — | — | CN | disclosed |
| CN-114874144-A | Process for preparing 4-bromo-N-arylpyrazole compound | 曲靖师范学院 | 2022-08-09 | — | — | CN | disclosed |
| EP-3112350-B1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9624177-B2 | Method for producing pyrazole compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20170008853-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3112350-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-7324259-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7324259-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008853-A1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | CBR3, POR, CBR1 | ALOX5 538/4885G6PD 210/4885ALOX15 574/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | ALOX5 1758/4885G6PD 3835/4885ALOX15 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.